Less than one in 10 individuals that would benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it releases its initial advice on the drugs.
Given over a billion individuals worldwide currently obese, it is calling for increased and just availability to this class of drugs.
According to projections, more than two billion are projected to be obese by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a lifelong illness that can be managed with thorough and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to universal availability to the jabs that can assist patients in reducing considerable body mass, says the body.
Skinny Jab Scarcity
Despite the current most favorable scenario, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of the global need, as stated by the health organization.
The advice urges governments and firms to widen access, via strategies such as patent sharing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is due to expire in several nations in 2026.
How Weight-Loss Injections Function
These medications mimick a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so users eat less.
People commonly see weight reduction in the initial weeks of commencing the weekly injections.
Research indicates people may see weight return after a year of discontinuing the treatment, when their normal hunger resume.
To be above a healthy weight raises your chance for contracting health problems, like diabetes, heart disease, stroke, and specific malignancies.
Obesity impacts individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
